ReviewThe Australasian journal of dermatology2020
COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement.
Review in The Australasian journal of dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- SARS-CoV-2 (COVID-19) vaccination in dermatology patients on immunomodulatory and biologic agents: Recommendations from the Australasian Medical Dermatology Group.The Australasian journal of dermatology · 2021Guideline
- Patients with specific skin disorders who are affected by COVID-19: What do experiences say about management strategies? A systematic review.Dermatologic therapy · 2020Pooled it
- Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review.Dermatologic therapy · 2020Pooled it
- Contributions of dermatologists to COVID-19 research: A brief systematic review.Dermatologic therapy · 2020Pooled it
- Article
- A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.Narra J · 2022Review
- Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies.Journal of clinical medicine · 2022Review
- COVID-19 Pandemic Impact on Severe Alopecia Areata Patients.Skin appendage disorders · 2022Article
- Impact of COVID-19 Pandemic on Patients with Atopic Dermatitis.Actas dermo-sifiliograficas · 2022Article
- [Impact of COVID-19 Pandemic on Patients with Atopic Dermatitis].Actas dermo-sifiliograficas · 2022Article
- Plasmapheresis: a feasible choice for bullous pemphigoid patients infected with SARS-CoV-2.International journal of dermatology · 2022Article
- Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection.Journal of personalized medicine · 2022Article
- Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination - A case report.Journal of cosmetic dermatology · 2021Article
- Treatment recommendations for patients with vitiligo during COVID-19.The Australasian journal of dermatology · 2021Article
- Impact of Inflammatory Immune Dysfunction in Psoriasis Patients at Risk for COVID-19.Vaccines · 2021Article
- Hypersensitivity reaction to Hyaluronic Acid Dermal filler following novel Coronavirus infection - a case report.Journal of cosmetic dermatology · 2021Article
- Skin manifestations of COVID-19 in children: Part 3.Clinical and experimental dermatology · 2021Review
- Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Article
- Management of patients with pemphigus vulgaris during the COVID-19 pandemic: Experience of a second level dermatology center.The Australasian journal of dermatology · 2021Article
- Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.Dermatologic therapy · 2021Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients on immunomodulators, including biologic agents and new small molecular inhibitors, for cutaneous disease, represent a potentially vulnerable population during the COVID-19 pandemic. There is currently insufficient evidence to determine whether patients on systemic immunomodulators are at increased risk of developing COVID-19 disease or more likely to have severe disease. As such, clinicians need to assess the benefit-to-risk ratio on a case-by-case basis. In patients with suspected or confirmed COVID-19 disease, all immunomodulators used for skin diseases should be immediately withheld, with the possible exception of systemic corticosteroid therapy, which needs to be weaned. In patients who develop symptoms or signs of an upper respiratory tract infection, but COVID-19 is not yet confirmed, consider dose reduction or temporarily cessation for 1-2 weeks. In otherwise well patients, immunomodulators and biologics should be continued. In all patients, and their immediate close contacts, the importance of preventative measures to minimise human-to-human transmission cannot be overemphasised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.